Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 550

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 550
---
 73.4   ​    292,721   ​     76.1   ​    241,911   ​     77.7
Total                                    ​   348,884   ​    100.0   ​    384,447   ​    100.0   ​    311,103   ​    100.0
​
The following table sets forth the components of cost of revenue of our Other Ventures by product type for the years indicated.
​

                     ​                        ​      ​      ​     ​     ​       ​      ​     ​     ​       ​      ​     ​  
---------------------------------------------------------------------------------------------------------------------------
​                                                                                                   Year Ended December 31,
​                                             ​                  2024    ​                  2023    ​                  2022
​                                                   $’000           %          $’000           %          $’000           %
Cost of Revenue—Other Ventures                ​             ​            ​             ​            ​             ​        
Prescription drug products                    ​   254,138   ​    99.2    ​   284,927   ​    97.3    ​   228,968   ​    94.6
Healthcare products (incl. consumer health)   ​     1,963   ​     0.8    ​     7,794   ​     2.7    ​    12,943   ​     5.4
Total                                             256,101   100.0            292,721   100.0            241,911   100.0    
​
​

Research and Development Expenses
Our research and development expenses are attributable to our Oncology/Immunology operations. These costs primarily comprise the cost of research and development for our drug candidates, including clinical trial related costs such as payments to third-party CROs, personnel compensation and related costs, and other research and development expenses. The following table sets forth the components of our research and development expenses and the clinical trial related costs incurred for the development of our main drug candidates for the years indicated.
​

                    ​                        ​      ​      ​      ​     ​       ​      ​      ​     ​       ​      ​      ​  
-----------------------------------------------------------------------------------------------------------------------------
​                                            ​                                                        Year Ended December 31,
​                                            ​                   2024   ​                    2023   ​                    2022
​                                                  $’000            %          $’000            %          $’000